ABSTRACT
Advances in science and sequencing technologies together with observation of long-term follow-up studies provide now an in-depth analysis of genetic bases of cancer. Two studies from famous, highly specialized institutions, report that despite an overall good prognosis, some patients with very early breast cancer are presented with an aggressive phenotype, high recurrence and fatal outcome.
In this article, it is discussed whether these high-risk women are those with HER2-overexpressing tumors who might benefit from systemic treatment with the monoclonal antibody trastuzumab. Limitations of these studies and molecular systems approaches-based research directions are also discussed.
|
